Relmada Acquires Potential Therapy for Tourette

 Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from Asarina Pharma AB

Phase 2a results signaled improvement in Tourette symptoms, quality of life and robust overall safety, supporting Sepranolone as a new potential first line treatment option for TS

Sepranolone (isoallopregnanolone) is a first-in-class compound from new subgroup of neurosteroids known as GAMSAs- GABAA Modulating Steroid Antagonists - acting selectively on the GABAA pathway, potentially alleviating the negative effect of Allopregnanolone in Tourette syndrome and other compulsive disorders

https://www.globenewswire.com/news-release/2025/02/06/3021947/0/en/Relmada-Therapeutics-Acquires-Potential-Therapy-for-Tourette-Syndrome-from-Asarina-Pharma-AB.html